MARKET

SNY

SNY

Sanofi FR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.72
+0.24
+0.50%
Pre Market: 48.08 -0.64 -1.31% 09:11 09/24 EDT
OPEN
48.64
PREV CLOSE
48.48
HIGH
48.93
LOW
48.64
VOLUME
4.83K
TURNOVER
--
52 WEEK HIGH
54.26
52 WEEK LOW
44.76
MARKET CAP
122.05B
P/E (TTM)
17.78
1D
5D
1M
3M
1Y
5Y
Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
Availability of the Q3 2021 Memorandum for modelling purposes Paris, France – September 24, 2021 - Sanofi announced today that its Q3 2021 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.c...
GlobeNewswire · 7h ago
AstraZeneca teams up with VaxEquity for self-amplifying RNA platform
AstraZeneca (NASDAQ:AZN) has partnered with VaxEquity to commercialize drugs based on the self-amplifying RNA (saRNA) platform of the latter. Originated from Imperial College London, the saRNA platform is similar to the
Seekingalpha · 21h ago
Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis
Zacks.com · 2d ago
RPT-BRIEF-Sanofi/Regeneron: to present new data on efficiency of Dupixent® (dupilumab)
reuters.com · 3d ago
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 i...
GlobeNewswire · 3d ago
Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe
Zacks.com · 4d ago
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. 
Benzinga · 4d ago
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC Phase 3 trial met its primary and key secondary endpointsLibtayo is one of two PD-(...
GlobeNewswire · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SNY. Analyze the recent business situations of Sanofi FR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SNY stock price target is 65.00 with a high estimate of 71.00 and a low estimate of 58.00.
EPS
Institutional Holdings
Institutions: 805
Institutional Holdings: 209.61M
% Owned: 8.37%
Shares Outstanding: 2.51B
TypeInstitutionsShares
Increased
221
8.50M
New
58
3.29M
Decreased
156
5.40M
Sold Out
39
779.69K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.99%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
Serge Weinberg
Chief Executive Officer/Executive Board/Director
Paul Hudson
Chief Financial Officer/Executive Vice President/Executive Board
Jean-Baptiste Chasseloup De Chatillon
Chief Human Resource Officer/Executive Vice President/Executive Board
Natalie Bickford
Executive Vice President/General Counsel/Executive Board
Karen Linehan
Executive Vice President/Executive Board
Olivier Charmeil
Executive Vice President/Executive Board
Philippe Luscan
Executive Vice President/Executive Board
John Reed
Executive Vice President/Executive Board
Arnaud Robert
Executive Vice President/Executive Board
William Sibold
Executive Vice President/Executive Board
Thomas Triomphe
Executive Vice President/Executive Board
Julie Van Ongevalle
Director
Christophe Babule
Director
Wolfgang Laux
Director
Barbara Lavernos
Director
Tran Yann
Independent Director
Rachel Duan
Independent Director
Lise Kingo
Independent Director
Patrick Kron
Independent Director
Fabienne Lecorvaisier
Independent Director
Melanie Lee
Independent Director
Carole Piwnica
Independent Director
Gilles Schnepp
Independent Director
Diane Souza
Independent Director
Thomas Sudhof
Declaration Date
Dividend Per Share
Ex-Div Date
03/23/2021
Dividend USD 1.9061
05/03/2021
03/05/2020
Dividend USD 1.1735676
04/30/2020
--
Dividend USD 1.722322
05/07/2019
02/07/2018
Dividend USD 1.860874
05/09/2018
02/16/2017
Dividend USD 1.577088
05/11/2017
02/19/2016
Dividend USD 1.630252
05/05/2016
02/25/2015
Dividend USD 1.618087
05/06/2015
02/11/2014
Dividend USD 1.9096
05/07/2014
02/12/2013
Dividend USD 1.862409
05/06/2013
02/09/2012
Dividend USD 1.75642
05/07/2012
05/02/2011
Dividend USD 1.8221
05/11/2011
02/12/2010
Dividend USD 1.62732
05/17/2010
02/11/2009
Dividend USD 1.41856
04/20/2009
02/12/2008
Dividend USD 1.510272
05/16/2008
03/05/2007
Dividend USD 1.14537
06/04/2007
03/06/2006
Dividend USD 0.912
06/02/2006
03/01/2005
Dividend USD 0.7993
06/02/2005
09/02/2004
Dividend USD 0.0304
09/27/2004
--
Dividend USD 0.5795
04/30/2004
--
Dividend USD 0.4897
05/28/2003
About SNY
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Webull offers kinds of Sanofi SA (ADR) stock information, including NASDAQ:SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.